Directed evolution identifies a household of APR-motif-enriched AAV capsid variants with human T cell tropism
We engineered an AAV capsid library utilizing AAV6 as a beginning serotype, given its prior use in human T cell gene-editing functions31,34,39. We carried out saturation mutagenesis on a pseudotyped AAV2/6 genome, comprising the AAV2 Rep area and the AAV6 Cap area flanked by AAV2 inverted terminal repeats (ITRs) (Fig. 1a). We focused VR-IV of the VP1 capsid protein (amino acids 454–460), a identified surface-exposed area concerned in host interplay and antibody neutralization40. For useful choice, we screened the library instantly in main human T cells. Peripheral blood mononuclear cells (PBMCs) from wholesome donors had been activated utilizing human CD3/CD28/CD2 T cell activator and transduced with the AAV capsid library at MOI = 1,000 (MOI = 500 for the third spherical of choice), that’s, 1,000 vg per cell. To complement for capsid variants able to profitable mobile entry, cells had been subjected to stringent washes to take away surface-bound and unbound viruses. Internalized viral DNA was extracted; then, the VR-IV area was amplified by PCR and subsequently recloned into the AAV6-based plasmid spine (the wild-type VR-IV DNA sequence was changed with EGFP to keep away from any capsid6 contamination through the library cloning) to generate a brand new capsid library for the subsequent spherical of choice (Fig. 1a). After three rounds of choice, high-throughput sequencing revealed over 3 million distinctive capsid variants within the preliminary library, which decreased to ~1 million variants after choice (Prolonged Knowledge Fig. 1a–c).

a, Schematic of AAV capsid evolution technique in human T cells. A pooled library of AAV6 capsid variants was advanced in activated human T cells. b, The NGS information evaluation of parental and every spherical of the advanced capsid library. Bubble plots present the result of capsid evolution and every bubble represents a singular capsid variant on the amino acid degree. Bubble measurement signifies the fold change of variants (n = 2 donors). c, Correlation evaluation of enrichment of the highest 1,000 AAV variants after the third spherical of choice throughout donor A (x axis) and donor B (y axis). Every level represents a singular variant, categorized as AAV6 (pink), APR variants (inexperienced) or non-APR variants (grey). The dashed black line represents the road of greatest match. The Pearson correlation coefficient (r = 0.813) and the corresponding P worth (P < 2.2 × 10−16) are indicated on the plot. d, Enrichment of variants over choice rounds in human T cells. Line graph displaying the % of reads for various variant teams throughout three rounds of choice in donor A and donor B. e, Motif enrichment evaluation of the highest 200 enriched capsids from the third-round advanced library. f, The 7-mer sequence of the highest ten enriched APR-containing variants.
The quantification evaluation revealed substantial enrichment of a household of variants harboring the APR motif at positions 455–457 of VR-IV, which ultimately dominated the library after three rounds of choice (Fig. 1b), together with AAV.APR31 with an amino acid insertion 454-AAPRANE-460. This enrichment sample was persistently noticed in libraries from two unbiased donors (Fig. 1b). Notably, wild-type AAV6 was additionally among the many high enriched variants early within the display screen, though the underlying mechanism stays unclear. Correlation evaluation of the highest 1,000 AAV variants after the third spherical of choice throughout the 2 donors confirmed a powerful optimistic correlation (Fig. 1c and Prolonged Knowledge Fig. 1d), demonstrating the reproducibility and robustness of the screening technique. We additional quantified the relative abundance of AAV6, APR variants and non-APR variants within the pool. Notably, the AAV.APR variants quickly emerged and dominated the inhabitants (Fig. 1d), whereas the non-APR variants progressively decreased due to their decrease transduction effectivity (Fig. 1d). Motif evaluation of the highest 200 enriched capsids revealed sturdy enrichment of the APR motif at positions 2–4 throughout the 7-mers (Fig. 1e,f and Supplementary Desk 1). Even among the many high 1,000 variants from each donor screens, the APR-containing capsids demonstrated considerably increased enrichment in comparison with the non-APR counterparts (Prolonged Knowledge Fig. 1e,f).
AAV.APR31 allows environment friendly transgene supply in human and mouse T and NK cells
To find out whether or not APR-containing AAV variants outperform AAV6 in T cell transduction, we centered on AAV.APR31, one of the vital enriched variants. First, we assessed its AAV packaging yield by producing a self-complementary AAV (scAAV) vector carrying an EGFP cassette (scAAV-CAG-EGFP) and a single-stranded AAV (ssAAV) vector carrying a CD22-CAR cassette (Fig. 2a). AAV.APR31 yielded 1.02 × 1014 vg per L and 1.63 × 1013 vg per L of medium for EGFP and CD22-CAR cassette packaging, respectively, in comparison with 2.29 × 1014 vg per L and a couple of.87 × 1013 vg per L for parental AAV6 underneath matched manufacturing situations (Fig. 2b). Though the packaging yield of AAV.APR31 was barely diminished relative to AAV6 (2.05-fold and 1.76-fold reductions for scAAV-CAG-EGFP and ssAAV-EFS-CD22-CAR manufacturing, respectively), the variant maintained sturdy vector manufacturing throughout distinct transgene cassettes, suggesting that the 454–460 motif substitution stays suitable with environment friendly AAV manufacturing. Subsequent, we evaluated the cell-surface binding and uptake of the brand new variant. Activated human T cells had been incubated with the virus at 4 °C to permit binding with out endocytosis. After stringent washes, vg per cell was quantified by qPCR. AAV.APR31 certain considerably extra vector than AAV6 (20.3 vg per cell versus 5.8 vg per cell at MOI = 50, 48.3 vg per cell versus 6.3 vg per cell at MOI = 100 and 252.7 vg per cell versus 49.6 vg per cell at MOI = 1,000) (Fig. 2c). To evaluate uptake, human T cells had been incubated with virus in a 37 °C incubator for two h, revealing dramatically increased internalization by AAV.APR31 (37.9 vg per cell versus 2.5 vg per cell at MOI = 50, 103.4 vg per cell versus 3.6 vg per cell at MOI = 100 and 1,319.3 vg per cell versus 34.9 vg per cell at MOI = 1,000) (Fig. 2nd).

a, Schematic of scAAV-CAG-EGFP and ssAAV-EFS-CD22-CAR constructs. b, AAV packaging capability of AAV6 and AAV.APR31. AAV titer was quantified as vg by qPCR. Knowledge are introduced because the imply values ± s.e.m. (n = 9 organic replicates for scAAV (EGFP), P = 0.0005; n = 5 organic replicates for ssAAV (CD22-CAR), P = 0.0307). c, The variety of AAVs certain to the human T cell floor, quantified as vg by qPCR. Knowledge are introduced because the imply values ± s.e.m. (n = 3 organic replicates, P = 0.0004). d, Variety of internalized AAVs by a 2-h incubation of AAV and human T cells in a 37 °C incubator. Knowledge are introduced because the imply values ± s.e.m. (n = 3 organic replicates, P < 0.0001). e, Schematic of AAV transduction and EGFP detection in Jurkat. f, Consultant move cytometry evaluation of EGFP expression following transduction of Jurkat cells with AAV6 or AAV.APR31 on the indicated MOIs. g, EGFP proportion and depth quantification of transduced Jurkat cells. MFI, imply fluorescence depth. Knowledge are introduced because the imply values ± s.e.m. (n = 3 organic replicates, P < 0.0001). h, Schematic of human PBMC isolation, activation, AAV transduction and move cytometry in human T cells. i,j, Move cytometry evaluation of EGFP expression following transduction of human T cells with AAV6 or AAV.APR31 on the indicated MOIs. Left, fluorescence histograms. Proper, EGFP quantification of transduced cells. Donor 300F (i) and donor E (j) had been used on day 5 after activation (n = 1 replicate with six totally different MOIs). okay, Consultant move cytometry evaluation of EGFP expression following transduction of human T cells with AAV6 or AAV.APR31 at MOIs of 250, 500 and a couple of,500. T cells had been used for transduction on day 2 after activation. l, The quantification of T cell transduction effectivity of AAV6 and AAV.APR31 in 4 wholesome donors. T cells had been used for transduction on day 2 after activation. Knowledge are introduced because the imply values ± s.e.m. (n = 4 donors, P = 0.003). m, The quantification of T cell transduction effectivity of AAV6 and AAV.APR31 in seven wholesome donors. T cells had been used for transduction on day 5 after activation. Knowledge are introduced because the imply values ± s.e.m. (n = 7 donors, P < 0.0001). On this determine, two-sided unpaired t-tests (b) and peculiar two-way analyses of variance (ANOVAs; c,d,g,l,m) had been used to judge statistical significance. *P < 0.05, **P < 0.01, ***P < 0.001 and **** P < 0.0001.
Supply information
We then in contrast useful transduction in Jurkat cells, an immortalized human T lymphocyte cell line. We packaged scAAV-CAG-EGFP both with AAV.APR31 or AAV6 after which transduced Jurkat at MOIs starting from 50 to 1,000; EGFP expression was measured by move cytometry 48 h later (Fig. 2e). Notably, AAV.APR31 achieved 26.47% EGFP-positive cells at an MOI of 100 versus 0.84% for AAV6, elevated to 58.07% versus 5.07% at an MOI of 250 and exceeded 90% at an MOI of 1,000 versus 18.13% for AAV6 (Fig. 2f,g). To independently validate these findings on the transcript degree, we quantified EGFP mRNA by reverse transcription (RT)–qPCR in the identical experimental situations. According to the move cytometry information, EGFP transcript ranges had been markedly increased in AAV.APR31-transduced Jurkat cells in comparison with AAV6 throughout all MOIs examined (Prolonged Knowledge Fig. 2a), confirming that the superior transduction effectivity of AAV.APR31 is mirrored at each mRNA and protein ranges. Lastly, we evaluated main T cells from a number of donors (Fig. 2h). Even at a comparatively low MOI of 250, AAV.APR31 outperformed AAV6 transduced at a a lot increased MOI of 10,000 (donor 300F: 16.7% versus 13.1%, respectively; donor E: 17.2% versus 15.0%, respectively) on day 5 after donor human T cell activation (Fig. 2i,j and Prolonged Knowledge Fig. 2b,c). To evaluate the applicability of AAV.APR31 throughout various genetic backgrounds and at totally different levels of T cell activation, we repeated the transduction experiments utilizing main human T cells from 11 further donors. 4 donors had been transduced at an early time level (day 2), whereas seven donors had been transduced at a later time level after T cell activation (day 5) (Fig. 2k–m). Persistently, AAV.APR31 exhibited sturdy transduction effectivity throughout all samples. We additionally evaluated the power of AAV.APR31 to transduce mouse CD8+ T and NK cells utilizing an EGFP reporter. AAV.APR31 demonstrated markedly increased transduction effectivity in comparison with parental AAV6 in each cell varieties (Prolonged Knowledge Fig. 2nd,e).
AAV.APR31-mediated potent site-specific transgene knock-in in human T cells
To evaluate the dependence on dosing, we focused the primary exon of the TRAC locus (a gene encoding the TCR alpha chain) to create common allogeneic T cells31,41,42 (Fig. 3a), which eliminates endogenous TCR signaling interference43. Human T cells had been electroporated with Cas9 ribonucleoprotein (RNP) after which transduced with both AAV6 or AAV.APR31 carrying an EGFP or CD22-CAR cassette (Fig. 3a,b). On the lowest MOI (250 vg per cell), AAV.APR31 achieved 30.95% EGFP knock-in versus 4.34% with AAV6 and roughly 60% knock-in at an MOI of 1,000 on day 5 after electroporation (Fig. 3c). We subsequent delivered a bigger (1,803 bp) CD22-CAR cassette to totally different donors. At an MOI of 100, AAV.APR31 yielded CD22‑CAR expression in 18.7% (Fig. 3d) and 14.85% (Fig. 3e) of T cells, in comparison with 1.49% and a couple of.21% for AAV6 (Fig. 3d,e and Prolonged Knowledge Fig. 2f,g). Even at an MOI of fifty, AAV.APR31 maintained 7.65% versus 1.47% in AAV6 (Fig. 3e). At a better MOI of 1,000, the variations in knock-in efficiencies between AAV.APR31 and AAV6 had been extra pronounced (57.8% versus 14.2%, 45.05% versus 12.8%; Fig. 3d,e). To substantiate that the noticed EGFP and CD22-CAR sign displays secure genomic integration relatively than residual episomal expression, cells transduced with AAV alone (with out electroporation) had been analyzed in parallel; no detectable EGFP or CD22-CAR expression was noticed on day 5 underneath these situations (Prolonged Knowledge Fig. 2h,i), demonstrating that the EGFP+ or CD22-CAR+ inhabitants within the enhancing experiments represents bona fide knock-in occasions.

a, Schematic of EFS-EGFP-poly(A) and EFS-CD22-CAR-poly(A) constructs within the AAV spine and knock-in technique within the TRAC locus. b, Schematic of the transgene knock-in pipeline in main human T cells. c, Move cytometry evaluation of EGFP expression following RNP electroporation and AAV transduction of human T cells. Left, fluorescence histograms. Proper, EGFP quantification of transduced cells (n = 2 donors). d,e, CD22-CAR integration effectivity was analyzed by move cytometry in 4 totally different donor sources of activated T cells. The knock-in effectivity was quantified by the variety of CD22-CAR-positive cells throughout a variety of MOIs (n = 2 donors for every experiment). f, CD22-CAR integration effectivity was analyzed by move cytometry in nonprestimulated bulk CD8+ T cells (n = 2 donors). The knock-in effectivity was quantified by the variety of CD22-CAR-positive cells throughout a variety of MOIs on day 7 after AAV transduction (n = 2 donors). g, Schematic of CD22-CAR knock-in on the TRBC1 locus. h, Quantification of CD22-CAR knock-in effectivity throughout the indicated MOIs. Knowledge are introduced because the imply values ± s.e.m. (n = 4 donors, P < 0.0001). i, Schematic of BFP knock-in on the GAPDH locus. j, Quantification of BFP knock-in effectivity throughout the indicated MOIs. Knowledge are introduced because the imply values ± s.e.m. (n = 3 donors, P < 0.0001). okay, Consultant move cytometry plots displaying twin AAV-mediated supply of EGFP and BFP to the TRAC and GAPDH loci, respectively, at MOIs of 250 and 1,000. l, Quantification of EGFP +BFP+ double-positive cells throughout 4 MOIs (n = 1 donor with 4 totally different MOIs). m, Consultant move cytometry plots displaying simultaneous knock-in of MSLN-CAR and CD22-CAR into the TRAC and GAPDH loci, respectively, at MOIs of 250 and 1,000. n, Quantification of MSLN-CAR+CD22-CAR+ double-positive cells throughout 4 MOIs (n = 1 donor with 4 totally different MOIs). On this determine, peculiar two-way ANOVAs (h,j) with out adjustment had been used to judge statistical significance. ****P < 0.0001.
Supply information
To evaluate whether or not AAV.APR31 leads to aberrant will increase in vector genome integration, we quantified knock-in CAR copy quantity per cell by qPCR in AAV6-transduced and AAV.APR31-transduced T cells. On condition that our strategy targets a single genomic locus, the theoretical most integration is 2 copies per cell (one per allele). We noticed that the imply CAR copy quantity in AAV.APR31-transduced cells was akin to that of AAV6-transduced cells (1.34 versus 1.69 copies per cell; Prolonged Knowledge Fig. 2j) and neither group exceeded the anticipated diploid most of two copies per cell. These findings point out that the superior knock-in effectivity of AAV.APR31, mirrored by a better frequency of CAR+ cells, is pushed by an elevated proportion of efficiently edited cells relatively than by supraphysiological multicopy integration occasions. Moreover, the absence of copy numbers > two means that AAV.APR31 doesn’t promote off-target random integration, per the site-specific nature of homology-directed restore (HDR)-mediated knock-in.
Deliberate ex vivo pre-stimulation with anti-CD3/anti-CD28 is usually used to render T cells permissive to HDR-mediated knock-in; nonetheless, much less differentiated T cells can produce stronger CAR-T cells44. Due to this fact, we assessed whether or not AAV.APR31 may assist knock-in in bulk CD8+ T cells that weren’t intentionally prestimulated ex vivo (Fig. 3b). As a result of HDR is restricted to biking cells, we characterised the activation state of the cells earlier than enhancing. In comparison with antibody-activated T cells (day 2: 91.9% CD69+, 95.0% CD25+; day 4: 41.3% CD69+, 94.5% CD25+), nonprestimulated cells confirmed solely partial activation (40.3% CD69+, 5.7% CD25+) (Prolonged Knowledge Fig. 2k,l) whereas retaining {a partially} detectable Ki67+ fraction (Prolonged Knowledge Fig. 2m). Below these situations, AAV.APR31 mediated environment friendly knock-in that markedly exceeded AAV6 (13% versus 1.99% at MOI = 100; 35.8% versus 2.95% at MOI = 1,000) (Fig. 3f). As anticipated, knock-in in nonprestimulated CD8+ T cells was decrease than in prestimulated T cells, per the upper activation and bigger biking fraction of the latter rendering them extra permissive to HDR.
To check this knock-in system at different genomic loci, we carried out DNA knock-in throughout the TRBC1 and GAPDH loci of the human T cell genome (Fig. 3g,i). We noticed locus-dependent knock-in efficiencies, probably reflecting RNP reducing charges. At TRBC1 exon 1, AAV.APR31 produced knock-in efficiencies of 24.08% at MOI = 250 (versus 4.12% with AAV6) and 48.3% at MOI = 1,000 (versus 10.34% with AAV6) (Fig. 3h). At GAPDH exon 9, AAV.APR31 reached 36.4% and 56.87% of BFP-positive cells at MOIs of 250 and 1,000, respectively (Fig. 3j).
Delivering a number of genetic parts to a number of desired genomic loci could be technically difficult, particularly in cells which can be troublesome to transfect, corresponding to main human T and NK cells. To guage multiplex enhancing utilizing AAV.APR31, we concurrently delivered two HDR templates focusing on the TRAC and GAPDH loci. Twin knock-in was achieved in 26.1% of cells at MOI = 250 (versus 0.6% for AAV6) and 50.8% at MOI = 1,000 (versus 15.7% for AAV6) (Fig. 3k,l). To additional take a look at the effectivity of twin knock-in by AAV.APR31, we concurrently focused MSLN-CAR and CD22-CAR into the TRAC and GAPDH loci, respectively. AAV.APR31 enabled twin knock-in in 34.4% of cells at MOI 250 (versus 0.5% for AAV6) and 40.6% at MOI 500 (versus 2.65% for AAV6) (Fig. 3m,n). The overall knock-in effectivity of the TRAC locus (MSLN-CAR) reached 56.8% of cells at MOI = 250 (versus 3.8% for AAV6) and the GAPDH locus (CD22-CAR) reached 55.0% of cells at MOI = 250 (versus 9.0% for AAV6) (Fig. 3m).
Genome-scale CRISPR screens determine important genes for AAV.APR31 transduction in human T cells
To elucidate the mechanistic alterations of AAV.APR31 that improves its transduction effectivity over AAV6, we carried out genome-scale CRISPR knockout (KO) screens to determine genes important for AAV.APR31-mediated transduction in Jurkat cells, an immortalized T cell line, with comparable transduction effectivity in human main T cells. To differentiate T cell-specific components, we carried out a parallel CRISPR display screen in NALM-6, a human B lymphocyte line, serving as a lineage management (Fig. 4a). First, we generated Cas9-expressing Jurkat and NALM-6 cell traces (Jurkat-Cas9 and NALM-6-Cas9) and transduced them with the Brunello sgRNA library45. Following puromycin choice, the ensuing heterogeneous cell populations, every containing distinct gene KOs, had been transduced with AAV.APR31 carrying an EGFP cassette (Fig. 4a). Cells had been then sorted and sequenced on the premise of EGFP expression into populations with excessive (high 18%) and low (backside 18%) fluorescence (Fig. 4b).

a, Schematic of genome-wide KO screens in Jurkat (T lymphocytes) and NALM-6 (B lymphocytes) cells to determine genes particularly for AAV.APR31 transduction in T lymphocytes. b, Move sorting technique of Jurkat-Cas9 and NALM-6-Cas9 cells (transduced with Brunello library) after scAAV-CAG-EGFP transduction. c, Scatter plots of median sgRNA log2 fold change (EGFPlow/excessive sorting bins) for every gene in two consultant replicates of Jurkat display screen. FC, fold change. d, sgRNA log2 fold adjustments for genes of the highest enriched bin within the Jurkat display screen. Bars signify the imply log2 fold change for every sgRNA throughout three unbiased replicates. The density plots above signify the distribution of all sgRNAs. e, Comparability of gene log2 fold change (median sgRNA, imply of three replicates) in Jurkat and NALM-6 screens. f, Cas9 RNP-mediated CD7 KO in Jurkat. Consultant move plots measuring CD7 expression after Cas9 RNP electroporation. g, Consultant fluorescence histograms of Jurkat cells transduced with scAAV-CAG-EGFP after CD7 KO. h, Quantification of EGFP fluorescence depth in Jurkat cells after CD7 KO (MOI = 1,000). Knowledge are introduced because the imply ± s.e.m. (n = 3 organic replicates, AAVS1-sg versus CD7-sg1: P < 0.0001, AAVS1-sg versus CD7-sg2: P < 0.0001). i, Cas9 RNP-mediated CD7 KO in human T cells. Consultant move plots of CD7 expression after Cas9 RNP electroporation. j, Quantification of EGFP fluorescence depth in human T cells after CD7 KO (MOI = 10,000; (n = 2 donors). okay, Quantification of EGFP fluorescence depth in Jurkat cells that had been pretreated with anti-human CD7 antibody. Knowledge are introduced because the imply values ± s.e.m. (n = 3 organic replicates, q < 0.0001 (IgG), q < 0.0001 (0.4 μg ml−1), q < 0.0001 (1 μg ml−1), q < 0.0001 (2 μg ml−1), q < 0.0001 (4 μg ml−1)). l, Quantification of EGFP depth in human T cells that had been pretreated with anti-human CD7 antibody (MOI = 10,000). Knowledge are introduced because the imply values ± s.e.m. (n = 3 donors, q = 0.0009 (IgG), q = 0.4589 (0.4 μg ml−1), q = 0.6839 (1 μg ml−1), q = 0.4589 (2 μg ml−1), q = 0.5301 (4 μg ml−1)). m, Consultant move plot of NALM-6 with CD7 overexpression. n, Quantification of EGFP fluorescence depth in NALM-6 and NALM-6-CD7 cells after scAAV-CAG-EGFP transduction at totally different MOIs. Knowledge are introduced because the imply values ± s.e.m. (n = 3 organic replicates, CD7−-AAV.APR31 versus CD7+-AAV.APR31: P < 0.0001, CD7+-AAV6 versus CD7+-AAV.APR31: P < 0.0001). o, Quantification of EGFP expression in Jurkat cells transduced with scAAV-CAG-EGFP preincubated with recombinant human AAVR PKD1–PKD5 area protein on the indicated concentrations. Recombinant EGFP protein was included as a damaging management (MOI = 1,000). p,q, Consultant BIAcore sensorgrams displaying the binding of recombinant human AAVR PKD1–PKD5 area protein to immobilized AAV6 (p) and AAV.APR31 (q) on the indicated analyte concentrations. The related price fixed (Oka), dissociation price fixed (Okd) and equilibrium dissociation fixed (OkD) are indicated in every panel. RU, resonance models. r, Major human CD8+ T cells, CD4+ T cells, NK cells, B cells and monocytes had been transduced with scAAV-CAG-EGFP at an MOI of 250. EGFP expression was assessed utilizing move cytometry 48 h after transduction. Knowledge are introduced because the imply values ± s.e.m. (n = 3 donors, CD8+ T cells, q < 0.0001; n = 3 donors, CD4+ T cells, q < 0.0001; n = 3 donors, NK cells, q = 0.0248; n = 2 donors, B cells; n = 2 donors, monocytes). s, The AlphaFold 3-predicted buildings of VR-IV domains of AAV6 and AAV.APR31 and the extracellular area of CD7. t, The conformation and interactions (highlighted in cyan) of the AAV.APR31 monomer and CD7, with the VR-IV area protruding towards CD7, establishing a powerful interplay with corresponding residues within the extracellular area of CD7. u, The core of the interplay interface between the AAV.APR31 VR-IV area and CD7. The interplay residues are highlighted in orange and cyan. On this determine, two-sided unpaired t-tests (h), a number of two-sided unpaired t-tests (q worth; okay,l,r), and two-way ANOVAs with Tukey’s multiple-comparison checks (adjusted P worth; n) had been used to judge statistical significance. NS, not important; *P < 0.05, ***P < 0.001 and ****P < 0.0001.
Supply information
Subsequent sgRNA quantification confirmed the enrichment of a number of identified and novel host components. Within the Jurkat display screen, genes corresponding to CD7, TM9SF2, KIAA0319L, VPS52, VPS51, VPS16, ATP2C1, TRAPPC1, GPR108, KPNA6, NR4A1, HELQ, KMT2D, SASH3, COG4, OSBPL8 and SLC35B2 had been strongly enriched (Fig. 4c,d and Supplementary Desk 2). In distinction, the NALM-6 display screen revealed sturdy enrichment of TM9SF2, KIAA0319L, ST3GAL4, ATP2C1, NAA10, VPS52, VPS51, VPS29, JTB, LUC7L3, WDR24, GPR107, GPR108 and MAX (Prolonged Knowledge Fig. 3a,b and Supplementary Desk 3). Notably, top-ranked hits overlapped between the 2 screens, together with KIAA0319L (also referred to as AAVR) (Fig. 4e), a well-established and important receptor for AAV an infection46, in addition to TM9SF2, GPR108, VPS52, VPS51 and ATP2C1 (Fig. 4e), all of which have beforehand been implicated in AAV biology46,47. These targets highlighted a number of mobile elements and molecular features that had been positively related to AAV an infection, together with the Golgi equipment subcompartment, the vesicle tethering advanced, the histone methyltransferase advanced, the methyltransferase advanced, phospholipase binding and the MLL3/4 advanced, which might all contribute to AAV.APR31 transduction (Prolonged Knowledge Fig. 3c). The recurrence of those canonical AAV infection-related genes strongly helps the robustness and specificity of our screens. Comparative enrichment evaluation between the Jurkat and NALM-6 screens highlighted CD7 (also referred to as GP40) as a high candidate particularly enriched within the Jurkat cells however not in NALM-6 cells (Fig. 4e). CD7 encodes a transmembrane protein belonging to the immunoglobulin superfamily and serves as a lineage marker, with expression detected on T cells48,49 and NK cells50. These findings recommend that the interplay between CD7 and AAV.APR31 enhances its transduction effectivity particularly in CD7-positive Jurkat cells however not in CD7-negative NALM-6 cells, supporting the potential position of CD7 as a lineage-specific entry issue.
To find out whether or not CD7 was required for AAV.APR31 transduction, we generated Jurkat cell traces with CRISPR–Cas9 KO of CD7 or AAVS1 (damaging management) (Fig. 4f). Then, 5 days after electroporation with Cas9 RNPs, cells had been contaminated with scAAV‑CAG-EGFP at an MOI of 1,000 vg per cell. AAVS1‑KO cells remained totally transducible (~100% EGFP-positive), whereas CD7‑KO markedly diminished AAV.APR31 transduction, whereas AAV6 was solely modestly affected (Fig. 4g,h). We validated these findings in main human T cells from two donors and confirmed that disruption of CD7 considerably impaired AAV.APR31‑mediated transduction (Fig. 4i,j and Prolonged Knowledge Fig. 4a). To evaluate whether or not this CD7 dependency is conserved throughout species, we carried out CRISPR-mediated Cd7 KO in main mouse T cells, which equally resulted in a major however partial discount in AAV.APR31 transduction effectivity (Prolonged Knowledge Fig. 4b). Furthermore, pretreatment of Jurkat and human T cells with an anti‑human CD7 antibody considerably inhibited AAV.APR31 transduction however had little impact on AAV6 (Fig. 4k,l and Prolonged Knowledge Fig. 4c). The outcomes collectively confirmed that disruption of interactions between AAV.APR31 and CD7, both by CD7 KO or antibody blocking, considerably hindered AAV.APR31 transduction in Jurkat cells and human and mouse T cells. Notably, CD7 disruption didn’t utterly abolish AAV.APR31 transduction, suggesting that CD7 isn’t the only determinant of viral entry. To additional verify the position of CD7 in AAV.APR31-mediated transduction, we overexpressed CD7 in a CD7-negative cell line, NALM-6 (Fig. 4m), after which evaluated whether or not the gain-of-expression of CD7 may get well AAV.APR31 transduction. As anticipated, NALM-6 CD7-expressing cells confirmed considerably elevated AAV.APR31 transduction in comparison with wild-type CD7-negative NALM-6 cells in the identical pool (Fig. 4n). To discover the connection between CD7 expression degree and AAV.APR31 transduction effectivity, we in contrast Jurkat (CD7-high), Ok‑562 (CD7-low) and NALM‑6 (CD7-negative) cells (Prolonged Knowledge Fig. 4d). We discovered that AAV.APR31 transduction effectivity correlated instantly with CD7 abundance on the cell membrane, whereas AAV6 remained unchanged throughout all traces (Prolonged Knowledge Fig. 4e–g).
To research the CD7-independent entry pathway that accounts for residual transduction, we examined the position of the canonical AAV receptor AAVR. Preincubation of AAV6 and AAV.APR31 with soluble human AAVR polycystic kidney illness (PKD) domains 1–5 (Prolonged Knowledge Fig. 4h), the important thing extracellular construction that interacts with the AAV capsid51,52, progressively blocked transduction of each vectors in Jurkat cells in a concentration-dependent method (Fig. 4o), demonstrating that AAV.APR31 retains dependence on the canonical AAVR entry pathway. Floor plasmon resonance (SPR) evaluation additional revealed that AAVR binds AAV.APR31 with an affinity of 397 nM, in comparison with 230 nM for parental AAV6 (Fig. 4p,q), indicating that the APR motif substitution modestly reduces however doesn’t abolish AAVR binding. Collectively, these information assist a layered-entry mannequin by which AAV.APR31 makes use of AAVR-mediated canonical entry as a baseline pathway, whereas CD7 engagement supplies a further and dominant enhancement particularly in T and NK cells, explaining each the residual transduction in CD7-negative contexts and the considerably elevated effectivity in CD7-expressing lymphoid cells.
To evaluate whether or not this CD7-dependent tropism extends to main human immune cells and confers selectivity in a physiologically related context with a number of cell varieties, we transduced purified main human T cells, NK cells, B cells and monocytes individually underneath cell-type-appropriate tradition situations at a hard and fast MOI of 250 vg per cell. AAV.APR31 achieved markedly increased transduction effectivity than AAV6 in all CD7-expressing populations: 61.7% versus 8.2% in CD8+ T cells, 49.9% versus 6.7% in CD4+ T cells and 35.8% versus 9.8% in NK cells (Fig. 4r). In distinction, each AAV.APR31 and AAV6 confirmed comparably low transduction in CD7-negative B cells (1.44% versus 1.25%) and monocytes (0.66% versus 0.41%), with no important enhancement by AAV.APR31 over AAV6 in these populations (Fig. 4r). The magnitude of AAV.APR31-mediated enchancment throughout cell varieties correlated with their respective CD7 expression ranges, per the sample noticed throughout cell traces and additional supporting CD7 as the first determinant of AAV.APR31’s preferential lymphoid tropism.
We subsequent assessed whether or not amino acid insertion 454-AAPRANE-460 adjustments the spatial conformation of the VR-IV area between AAV6 and AAV.APR31. We carried out AlphaFold 3 prediction of the buildings of the capsid monomer for AAV6 and AAV.APR31, in addition to the construction of CD7 (Fig. 4s). The structural modeling revealed a brand new conformation of the VR-IV area in AAV.APR31 monomer, with shut interplay between the VR-IV area of AAV.APR31 and CD7 extracellular construction (Fig. 4t,u). This interplay was not noticed between AAV6 and CD7. The VR-IV area of AAV.APR31 engaged with CD7 by way of key residues throughout the interplay interface (highlighted in orange and cyan), significantly throughout the APR motif, which extends towards CD7 and creates a complementary contact interface (Fig. 4t,u). The VR-IV area centered on the APR motif preferentially fashioned electrostatic interactions or hydrogen bonds with residues situated on the floor of CD7. The general complementary protein floor interactions between AAV.APR31 monomer and CD7 additional assist the improved transduction capability of AAV.APR31 to human T cells.
AAV.APR31-mediated therapeutic immune cell era for cell remedy
We subsequent utilized this method to engineer varied therapeutic transgenes in main human T cells and NK cells, together with stable tumor-targeting CAR-T cells (MSLN-CAR and GD2-CAR), bispecific or tandem (CD19.20) CAR-T cells, TCR-T cells and CAR-NK cells (Fig. 5a). We designed HDR templates focusing on exon 1 of the TRAC locus primarily based on an AAV spine (Fig. 5b) and the donor templates had been packaged utilizing both AAV6 or AAV.APR31. For stable tumor-targeting CAR-T cells, we generated MSLN-CAR and GD2-CAR-T cells utilizing various AAV doses and in contrast the efficiency of AAV6 and AAV.APR31. AAV.APR31 achieved markedly increased knock-in efficiencies, yielding 36.8%, 57.1%, 66.3%, 71.0% and 72.4% MSLN-CAR-positive T cells at MOIs starting from 100 to 1,000 on day 4 after transduction (Fig. 5c). In distinction, AAV6 solely achieved 0.92%, 3.48%, 8.25%, 11.7% and 18.9% CAR-positive T cells underneath the identical situations (Fig. 5c). An identical development was noticed within the era of GD2-CAR-T cells, the place AAV.APR31-mediated DNA knock-in exhibited considerably improved effectivity in comparison with AAV6 (Fig. 5d).

a, Schematic of the therapeutic immune cell era move chart utilizing AAV6 or AAV.APR31. b, Schematic of MSLN-CAR, GD.2-CAR, CD22-CAR, CD19.20-CAR and NY-ESO-1 TCR buildings in AAV spine. c–e, MSLN-CAR (c), GD.2-CAR (d) and CD19.20-CAR (e) integration into the TRAC locus in activated human T cells. The knock-in effectivity was quantified by the variety of CAR-positive cells throughout a variety of MOIs. Left, fluorescence histograms. Proper, quantification of CAR-positive cells (n = 1 donor for every assemble with 5 totally different MOIs. f, NY-ESO-1 TCR knock-in effectivity within the TRAC locus. The knock-in effectivity was quantified by the variety of EGFP-positive cells throughout a variety of MOIs. Left, fluorescence histograms. Proper, quantification of TCR-positive cells (n = 1 donor with 5 totally different MOIs. g, Consultant fluorescence histograms of CD22-CAR in main human NK cells. h, The knock-in effectivity of CD22-CAR into the TRAC locus was quantified by the variety of CD22-CAR-positive NK cells throughout a variety of MOIs. Knowledge are introduced because the imply values ± s.e.m. (n = 4 donors, P < 0.0001). i, Schematic of the AAV-SB system and its supply process. j, Consultant move plots of human T cells transduced with the AAV-SB system. okay, The mixing effectivity was quantified by the variety of EGFP-positive cells throughout a variety of MOIs on day 7 after AAV transduction (n = 1 donor with three totally different MOIs). l,m, Head-to-head comparability of AAV6, AAV-hT7 and AAV.APR31 in main human T cells. l, Transient scAAV-CAG-EGFP transduction effectivity (CD3+EGFP+) in main human T cells transduced with AAV6, AAV-hT7 or AAV.APR31 at an MOI of 250. Knowledge are introduced because the imply values ± s.e.m. (n = 3 donors, AAV-hT7 versus AAV6: P < 0.0001, AAV.APR31 versus AAV6: P < 0.0001, AAV.APR31 versus AAV-hT7: P = 0.0002). m, TRAC locus site-specific knock-in effectivity of CD22-CAR in main human T cells codelivered with CRISPR–Cas9 RNP and the indicated AAV donor template at an MOI of 250. Knowledge are introduced because the imply values ± s.e.m. (n = 4 donors, AAV-hT7 versus AAV6: P < 0.0001, AAV.APR31 versus AAV6: P < 0.0001, AAV.APR31 versus AAV-hT7: P = 0.0028). n, Correlation evaluation of log2 fold adjustments in gene expression between AAV6-generated and AAV.APR31-generated CAR-T cells, cells had been collected at two totally different time factors (16 h versus 7 days, P < 2.2 × 10−16). On this determine, peculiar two-way ANOVAs (h), two-sided unpaired t-tests (l,m) and two-sided Pearson correlation analyses (n) had been used to judge statistical significance. **P < 0.01, ***P < 0.001 and ****P < 0.0001.
Supply information
Focusing on a single tumor antigen has proven limitations in medical settings, as some individuals relapse or don’t reply to CAR-T remedy due to antigen loss or downregulation12,53, such because the CD19 antigen54,55,56. Bispecific CAR-T cells can overcome this by synergistically enhancing tumor cell killing when each goal antigens are current57,58,59. To guage the supply effectivity of bispecific CAR in human T cells, we designed a tandem scFv assemble focusing on CD19 and CD20, which was packaged utilizing both AAV6 or AAV.APR31 (Fig. 5b). Persistently, AAV.APR31 achieved superior knock-in effectivity with the CRISPR system, producing 46.1%, 68.8%, 75.6%, 78.5% and 79.5% CD19.20-CAR-positive T cells at MOIs starting from 100 to 1,000 on day 4, even with the big knock-in fragment (2,645 bp) (Fig. 5e).
Not like CAR-T cells, TCR-T cells acknowledge intracellular tumor antigens introduced by MHC molecules, increasing the spectrum of targetable antigens. To discover the broader applicability of AAV.APR31, we cloned an NY-ESO-1 TCR assemble together with an EGFP marker into the AAV spine. Move cytometry evaluation indicated environment friendly NY-ESO-1 TCR knock-in, attaining as much as 21.1% at MOI = 100 and 41.1% at MOI = 1,000 (Fig. 5f). To guage transgene stability, we carried out move cytometry evaluation on day 7 after electroporation and AAV transduction, which confirmed even increased knock-in efficiencies and secure expression ranges (Prolonged Knowledge Fig. 4i).
Not like T cells, NK cells are innate lymphoid cells important for controlling viral infections and tumors60. They don’t require HLA matching and sometimes don’t trigger graft-versus-host illness, making them ideally suited candidates for ‘off-the-shelf’ cell therapies, corresponding to CAR-NK cells. We generated CD22-CAR knock-in NK cells with AAV.APR31 utilizing main human NK cells (Fig. 5a). AAV.APR31 achieved excessive knock-in efficiencies, yielding 10.6%, 20.8%, 34.0%, 39.3% and 48.4% CD22-CAR-positive NK cells (4 donors) at MOIs starting from 100 to 1,000 on day 5 after transduction (Fig. 5g,h). In distinction, AAV6 solely achieved 5.7%, 6.6%, 9.5%, 12.7% and 13.8% CD22-CAR-positive NK cells underneath the identical situations (Fig. 5g,h).
To provide therapeutic immune cells effectively, we beforehand developed a gene supply system, MAJESTIC61, which allows high-quality and high-yield manufacturing of various therapeutic immune cell varieties. Nonetheless, the MAJESTIC system requires excessive AAV MOIs to attain optimum supply effectivity. To evaluate whether or not AAV.APR31 may improve this method at decrease AAV doses, we packaged a SB transposon assemble into AAV (AAV-SB) utilizing both AAV6 or AAV.APR31 after which codelivered it with SB transposase mRNA by electroporation (Fig. 5i). AAV.APR31 achieved considerably increased integration efficiencies, yielding 52.5%, 59.7% and 58.7% of EGFP-positive cells at MOIs of 250, 500 and 1,000, respectively, whereas AAV6 solely achieved 1.86%, 3.25% and seven.02% underneath the identical situations (Fig. 5j,okay). To substantiate that the noticed EGFP sign displays real transposon integration relatively than residual episomal expression, we transduced T cells with AAV-SB-EGFP within the absence of SB transposase mRNA. Below these situations, EGFP expression was not detectable above background on day 7 after transduction (Prolonged Knowledge Fig. 4j), demonstrating that episomal AAV doesn’t contribute to the sign on the time factors used for evaluation.
We benchmarked AAV.APR31 in opposition to the lately reported AAV-hT7 variant advanced from AAV6 (ref. 38) in main human T cells utilizing two unbiased readouts. For transient transgene supply, AAV.APR31 achieved 85.17% CD3+EGFP+ cells in comparison with 67.67% for AAV-hT7 and 12.67% for parental AAV6 (Fig. 5l). For site-specific knock-in, AAV.APR31 yielded 67.83% CD22-CAR+ cells in comparison with 51.3% for AAV-hT7 and 18.35% for AAV6 (Fig. 5m). In each assays, AAV.APR31 considerably outperformed AAV-hT7, demonstrating superior T cell supply effectivity throughout each transient expression and secure genomic integration modalities.
To additional assess the affect of viral transduction on T cells, we carried out transcriptome profiling of CAR-T cells generated utilizing AAV6 or AAV.APR31. CD22-CAR constructs had been knocked into exon 1 of the TRAC locus by way of Cas9 RNP electroporation, adopted by AAV transduction (MOI = 1,000) in T cells from two totally different donors. Cells had been harvested at 16 h and seven days after transduction for RNA extraction and sequencing to seize early and late transcription alterations. Principal part evaluation (PCA) revealed that samples from every donor clustered collectively on the early time level, regardless of the therapy situation, indicating donor-specific transcriptomic options (Prolonged Knowledge Fig. 5a). By day 7, all samples, together with RNP solely, RNP + AAV6 and RNP + AAV.APR31 teams, clustered collectively, suggesting that donor-related variability diminished over time (Prolonged Knowledge Fig. 5a). Differential gene expression evaluation at this later time level of day 7 confirmed a extremely comparable distribution of differentially expressed genes (DEGs) between AAV6 and AAV.APR31 teams (Prolonged Knowledge Fig. 5b and Supplementary Desk 4). The gene expression at two totally different time factors (16 h versus 7 days) underneath AAV6 and AAV.APR31 confirmed persistently upregulated or downregulated genes with no discordant course (|LFC| > 1 and q < 0.05; Fig. 5n, Prolonged Knowledge Fig. 5c,d and Supplementary Desk 4). On the early time level of 16 h, hierarchical clustering of high T cell function-related genes highlighted variation in activation and inhibitory-associated genes (PDCD1, CTLA4 and HAVCR2), in addition to naive and memory-associated genes (TCF7, SELL, LEF1, KLF2, KLF3 and FOXO1), between the 2 donors (Prolonged Knowledge Fig. 5e–g). Against this, on the later time level of day 7, inhibitory-associated genes (PDCD1, LAYN, HAVCR2, LAG3, CD244, CTLA4 and TIGIT), cytotoxic genes (GZMA, GZMB, GZMK, PRF1 and TNF) and lactate metabolism-related genes (SLC2A3, SLC2A8, GAPDH, PGK1, LDHA and IDH2) confirmed comparable expression patterns (Prolonged Knowledge Fig. 5e,h,i). At each time factors, samples had been clustered by donor supply relatively than AAV serotypes by hierarchical clustering with T cell function-related gene units. These findings point out that CAR-T cells generated utilizing AAV6 or AAV.APR31 exhibit comparable useful and transcriptional phenotypes throughout the similar donor, whereas interdonor variability stays a dominant supply of heterogeneity, probably due to inherent genetic variations.
CD7 expression profile throughout human tissues and cell varieties
To comprehensively outline the expression panorama of CD7 and assess the suitability of AAV.APR31 for extra translational functions, we analyzed public bulk and single-cell RNA-seq (scRNA-seq) datasets throughout varied human tissues and cell varieties. Cross-tissue bulk RNA-seq evaluation utilizing the Human Protein Atlas (HPA)62 revealed that CD7 expression was highest in lymphoid and digestive organs, together with the thymus, lymph node, appendix, spleen, small gut, tonsil and abdomen (Prolonged Knowledge Fig. 6a). Reasonable ranges had been noticed within the lung and liver (Prolonged Knowledge Fig. 6a), whereas most nonlymphoid tissues, such because the kidney, coronary heart, prostate, skeletal muscle, ovary and testis, exhibited negligible expression (Prolonged Knowledge Fig. 6a). This expression sample was independently validated by pseudobulk evaluation in a pan-tissue single-cell atlas throughout totally different sexes, tissues and datasets63, which reproduced the enrichment of CD7 in lymphoid and digestive tissues (Prolonged Knowledge Fig. 6b and Supplementary Fig. 1a).
To resolve the mobile origin of CD7 expression inside these tissues, we carried out gene expression and cell proportion analyses on the single-cell degree. CD7 expression was restricted primarily to T lymphocytes (CD8+ and CD4+ T cells), NK cells and innate lymphoid cells (Prolonged Knowledge Fig. 6c). The excessive expression of CD7 in immune and digestive system organs was attributed to a excessive proportion of those cell varieties (Prolonged Knowledge Fig. 6d and Supplementary Fig. 1b). Cell-type-specific expression throughout tissues confirmed this lineage specificity, displaying uniformly excessive expression of CD7 in CD4+ and CD8+ T cells and innate lymphoid cells throughout tissues, whereas B cells, myeloid cells, endothelial cells, epithelial cells and stromal cells persistently lacked CD7 expression (Prolonged Knowledge Fig. 6e). These findings exhibit the preferential restriction of CD7 to lymphoid lineages.
We subsequent centered on main lymphoid organs. Within the thymus, scRNA-seq revealed distinct developmental clusters, together with widespread lymphoid progenitor, double-negative and double-positive progenitors, in addition to mature subsets corresponding to naive CD4+ and CD8+ T cells, Treg cells and γδ T cells (Prolonged Knowledge Fig. 6f). CD7 expression was detectable all through the T cell developmental trajectory, with the strongest alerts in widespread lymphoid progenitor, double-negative, double-positive and mature T cell subsets, in addition to NK cells and innate lymphoid cells (Prolonged Knowledge Fig. 6f and Supplementary Fig. 1c). In distinction, nonlymphoid cell varieties corresponding to B cells, standard dendritic cells, monocytes and macrophages displayed persistently minimal or no expression. Within the bone marrow, CD7 expression was likewise confined to lymphoid clusters (T cells, innate lymphoid cells and NK cells) with negligible ranges in myeloid populations (for instance, neutrophils, monocytes and macrophages), mesenchymal stromal cells or B cells (Prolonged Knowledge Fig. 6g and Supplementary Fig. 1d). scRNA-seq evaluation of the central nervous system revealed no considerable CD7 expression throughout main resident cell varieties, together with neurons, astrocytes, microglia, oligodendrocytes and endothelial cells, apart from uncommon tissue-resident T cells (Supplementary Fig. 1e,f). Collectively, these information set up CD7 as a strong lineage-specific marker, with expression tightly restricted to T lymphocytes, their progenitors, innate lymphoid cells and NK cells throughout human tissues. Whereas AAV.APR31 entry isn’t completely depending on CD7 (as canonical AAVR-mediated pathways contribute to baseline transduction), the lineage-restricted expression of CD7 suggests preferential tropism towards T and NK cells in vivo.
To guage the in vivo tissue tropism of AAV.APR31 following systemic supply, we administered firefly luciferase (FFLuc)-packaged AAV6 and AAV.APR31 intravenously in mice and monitored bioluminescence alerts longitudinally utilizing an in vivo imaging system (IVIS). AAV6 exhibited sturdy liver tropism, as evidenced by sturdy hepatic bioluminescence alerts. In distinction, AAV.APR31 confirmed a markedly diminished liver sign, indicating partial detargeting from the liver following capsid engineering (Prolonged Knowledge Fig. 7a,b). As bioluminescence imaging lacks the sensitivity to resolve transduction variations in organs with decrease sign, we additional quantified FFLuc mRNA by RT–qPCR throughout six further tissues to acquire a extra complete organ-level biodistribution profile. AAV6 confirmed considerably elevated FFLuc mRNA within the lung in comparison with PBS controls, whereas AAV.APR31 exhibited considerably decrease lung transduction than AAV6, demonstrating diminished off-target supply to the lung (Prolonged Knowledge Fig. 7c). Within the spleen and kidney, each vectors confirmed comparable transduction ranges with no important distinction between teams (Prolonged Knowledge Fig. 7c). Within the coronary heart and mind, FFLuc mRNA ranges had been akin to PBS controls in all teams, indicating negligible transduction of those tissues by both vector (Prolonged Knowledge Fig. 7c). In skeletal muscle, AAV.APR31 confirmed a development towards diminished transduction in comparison with AAV6, though this distinction didn’t attain statistical significance (Prolonged Knowledge Fig. 7c). Collectively, these information exhibit that AAV.APR31 reveals an altered tissue tropism profile relative to parental AAV6, with diminished transduction within the liver and lung whereas sustaining comparable ranges in different tissues examined.
Preclinical antitumor efficacy of AAV.APR31-generated CAR-T cells
To guage the antitumor exercise of CAR-T cells generated with AAV6 or AAV.APR31 underneath the totally different MOIs, we generated antigen-specific CD22-CAR-T cells by transient expression and performed coculture assays utilizing varied bulk T cell-to-cancer cell ratios (Prolonged Knowledge Fig. 7d,e). The coculture information persistently demonstrated that AAV.APR31-derived CAR-T cells mediated considerably increased cytolysis of NALM-6-GL leukemia cells in comparison with AAV6-derived CAR-T cells. At 24 h, the killing effectivity of AAV.APR31-derived CAR-T cells was markedly superior throughout all examined MOIs and effector-to-target ratios (for instance, 5.8% versus 31.2% at MOI = 250, 4.3% versus 42.3% at MOI = 500 and 11.9% versus 53.5% at MOI = 1000 at a 1:2 ratio; Prolonged Knowledge Fig. 7f). Related tendencies had been noticed at 48 h, the place AAV.APR31-derived CAR-T cells maintained considerably increased cytolytic exercise (for instance, 20.9% versus 53.3% at MOI = 250, 40.0% versus 73.7% at MOI = 500 and 44.5% versus 83.7% at MOI = 1,000 at a 1:2 ratio; Prolonged Knowledge Fig. 7f). Nonetheless, there was no killing discrepancy if cytolysis was normalized by the share of CAR-positive cells (Prolonged Knowledge Fig. 7g). These variations in cytotoxicity are attributable to the upper fraction of CAR-expressing T cells achieved by AAV.APR31, because the superior transduction effectivity instantly interprets into higher useful output on the inhabitants degree.
To additional benchmark AAV.APR31 in opposition to the present medical normal for CAR-T manufacturing, we in contrast the antitumor performance of CAR-T cells generated by AAV.APR31, AAV6 and lentiviral vectors (Fig. 6a). To make sure a good useful comparability, CAR-T cells from all three methods (Fig. 6b) had been normalized to equal CAR-positive cell numbers earlier than useful evaluation. In vitro coculture cytotoxicity assays demonstrated comparable tumor killing exercise throughout all three methods, with no distinction in cytotoxicity amongst CAR-T cells derived from AAV.APR31, AAV6 and lentiviral vector at matched effector-to-target ratios (Fig. 6c and Prolonged Knowledge Fig. 7h). To validate these findings in vivo, CAR-T cells manufactured by every system had been evaluated in an SK-OV-3 xenograft stable tumor mannequin (Fig. 6a). Notably, all three methods produced CAR-T cells able to attaining full tumor elimination, with tumor-free outcomes noticed throughout all therapy teams (Fig. 6d,e and Prolonged Knowledge Fig. 7i). These outcomes set up that AAV.APR31-engineered CAR-T cells are functionally much like lentiviral vector-manufactured CAR-T cells in each in vitro and in vivo settings.

a, Schematic overview of CD22-CAR-T cell era with both AAV6 or AAV.APR31 and subsequent in vitro cytotoxicity assays. b, Consultant move plots of measuring CD22-CAR+ T cells. c, Cytolysis of NALM-6-GL leukemia cells in coculture assays at 24 h. Knowledge are introduced because the imply values ± s.e.m. (n = 3 replicates per donor, from three donors in complete). d, Tumor bioluminescence imaging quantification in NOG mice bearing SK-OV-3-PL tumors (5 × 106 cells per mouse) following therapy with PBS or MSLN-CAR-T cells manufactured utilizing lentiviral vector, AAV6 or AAV.APR31 (3 × 106 CAR-T cells per mouse). Luminescence alerts had been measured longitudinally from day 4 to day 19 after CAR-T cell administration. Knowledge are introduced because the imply values ± s.e.m. (n = 5 mice per group, PBS versus lentivirus: P < 0.0001, PBS versus AAV6: P < 0.0001, PBS versus AAV.APR31: P < 0.0001). e, Survival curves of SK-OV-3-PL tumor-bearing NOG mice handled as described in d (PBS versus lentivirus: P = 0.0044, PBS versus AAV6: P = 0.0044, PBS versus AAV.APR31: P = 0.0044). f, Schematic of the in vivo T cell supply effectivity experiment. Human T cells (3 × 106) and scAAV-CAG-EGFP packaged with AAV6 or AAV.APR31 capsids (5 × 1011 vg per mouse) had been administered intravenously into NOG mice on day 0. Spleens had been remoted on day 2 for move cytometric evaluation of EGFP expression (n = 5 mice per group). g, Consultant move cytometry plots displaying EGFP expression in human CD3+ T cells remoted from spleens of mice handled with PBS, AAV6 or AAV.APR31 at 48 h after injection. Numbers point out the share of EGFP+ cells throughout the gated inhabitants. h, Quantification of EGFP+ cells inside human CD3+, CD4+ and CD8+ T cell populations remoted from spleens of mice handled with PBS, AAV6 and AAV.APR31. Knowledge are introduced because the imply values ± s.e.m. (n = 5 mice per group, all q < 0.0001). i, Schematic of in vivo CAR-T era. NOG mice bearing established NALM-6-GL leukemia had been adoptively transferred with human T cells, adopted by tail-vein injection of AAV6 or AAV.APR31 encoding CD22-CAR (AAV dose: 5 × 1011 vg per mouse). j, Quantification of complete bioluminescence of leukemia-bearing mice. Knowledge are introduced because the imply values ± s.e.m. (n = 4 mice per group, PBS versus T cell solely: P = 0.474, PBS versus T cell + AAV6: P = 0.011, PBS versus T cell + AAV.APR31: P < 0.0001, T cell solely versus T cell + AAV6: P = 0.321, T cell solely versus T cell + AAV.APR31: P < 0.0001, T cell + AAV6 versus T cell + AAV.APR31: P = 0.008). okay, Survival curve of NALM-6-GL-induced leukemia-bearing NOG mice after T cell and AAV adoptive switch (PBS versus T cell solely: P = 0.0091, PBS versus T cell + AAV6: P = 0.0091, T cell + AAV6 versus T cell + AAV.APR31: P = 0.0266, T cell solely versus T cell + AAV.APR31: P = 0.0062, T cell solely versus T cell + AAV6: P = 0.9216). l, Schematic of the experimental design. NOG mice had been engrafted subcutaneously with human AsPC-1 pancreatic most cancers cells (day 0) and obtained human T cells on day 9. Mice had been subsequently handled with scAAV-MSLN-CAR packaged in AAV6 or AAV.APR31 on days 9, 11 and 13. m, Tumor development curves of tumor-bearing mice after receiving T cell and AAV adoptive switch. Knowledge are introduced because the imply values ± s.e.m. (n = 5 mice per group, PBS versus T cell solely: P = 0.8741, PBS versus T cell + AAV6: P = 0.9427, PBS versus T cell + AAV.APR31: P < 0.0001, T cell solely versus T cell + AAV6: P = 0.5562, T cell solely versus T cell + AAV.APR31: P < 0.0001, T cell + AAV6 versus T cell + AAV.APR31: P < 0.0001). On this determine, two-way ANOVAs with Tukey’s multiple-comparison checks (adjusted P worth; d,j,m), log-rank (Mantel–Cox) checks (e,okay) or two-sided unpaired t-tests (h) had been used to judge statistical significance. *P < 0.05, **P < 0.01 and ****P < 0.0001.
Supply information
To quantitatively assess in vivo transgene supply effectivity unbiased of antigen-driven T cell dynamics, we carried out an experiment by which human T cells had been adoptively transferred into non-tumor-bearing humanized NOG mice, adopted by systemic administration of scAAV-CAG-EGFP packaged with AAV.APR31 or AAV6 capsids (Fig. 6f). EGFP was chosen as a reporter to allow clear, unconfounded quantification of transduction effectivity. At 48 h after AAV administration, spleens had been remoted and analyzed by move cytometry. AAV.APR31 achieved considerably increased EGFP expression in human T cells in comparison with AAV6 (CD3+ T cells: 45.0% versus 18.2%, CD4+ T cells: 44.9% versus 18.2%, CD8+ T cells: 50.0% versus 20.8%; Fig. 6g,h).
To guage the translational potential of AAV.APR31 for direct in vivo CAR-T era, human T cells had been first adoptively transferred into immunodeficient mice bearing established NALM-6-GL leukemia, adopted by systemic administration of AAV.APR31 or AAV6 encoding a CD22-specific CAR (Fig. 6i). The AAV.APR31 group exhibited potent cytotoxicity, considerably decreasing leukemia burden as quantified by bioluminescence imaging and resulting in markedly improved survival in comparison with controls (Fig. 6j,okay). Against this, the AAV6 group confirmed minimal antitumor results and no survival profit, akin to T cell solely (Fig. 6j,okay). To additional assess its applicability in stable tumors, we established a human pancreatic most cancers (AsPC-1) mannequin and evaluated the antitumor efficacy of AAV.APR31-generated MSLN-CAR-T cells (Fig. 6l). According to its superior transduction effectivity, the T cell + AAV.APR31 group markedly suppressed tumor development in comparison with the T cell + AAV6 and management teams, leading to considerably diminished tumor burden (Fig. 6m).